| No. | Year | Trial | line | Design | median OS (mo) | HR (95%CI) | Ref no. |
|---|---|---|---|---|---|---|---|
| 1 | 2008 | SHARP | 1st | Sorafenib | 10.7 | 0.69 (0.55-0.87) | (4) |
| placebo | 7.9 | ||||||
| 2 | 2009 | Asian-Pacific | 1st | Sorafenib | 6.5 | 0.68 (0.50-0.93) | (23) |
| placebo | 4.2 | ||||||
| 3 | 2018 | REFLECT | 1st | Lenvatinib | 13.6 | 0.92 (0.79-1.06) | (24) |
| Sorafenib | 12.3 | ||||||
| 4 | 2017 | RESORCE | 2nd | Regorafenib | 10.6 | 0.63 (0.50-0.79) | (25) |
| Placebo | 7.8 | ||||||
| 5 | 2018 | CELESTIAL | 2nd | Cabozantinib | 10.2 | 0.76 (0.63-0.92) | (26) |
| Placebo | 8.0 | ||||||
| 6 | 2019 | REACH-2 | 2nd | Ramucirumab | 8.5 | 0.71 (0.53-0.95) | (27) |
| Placebo | 7.3 | ||||||
| 7 | 2020 | IMbrave150 | 1st | Atezolizumab + Bevacizumab | 19.2 | 0.66 (0.52-0.85) | (28) |
| Sorafenib | 13.4 |
